本帖最后由 老马 于 2013-3-13 13:43 编辑
- _) F' {8 F7 v9 z/ `) s( m- o3 z0 \* p. L9 z' Z" t4 f
健择(吉西他滨)+顺铂+阿瓦斯汀, C4 G$ m" F( s! F9 H
Gemzar +Cisplatin + Avastin
7 z8 ?% u3 }" c4 b, F8 l; I# ihttp://annonc.oxfordjournals.org/content/21/9/1804.full
+ ]7 i( k( b! U' pOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 A' T% E, R4 c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ( ^( ~) s2 l8 W+ {
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 u1 _" |+ p8 m, ~
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 874)
' c- `& J/ t! J s华为网盘附件:2 _- d8 H! F9 I7 F; {4 u
【华为网盘】ava.JPG
7 F: ?$ l6 B* Q, E- d9 w# e |